Selentus is pleased to announce an investment from Pioneer Group to support the development of our surgical haemostat, TenaTac®, an innovative medical device that controls bleeding during a surgical procedure while also reducing the risk of post-operative haemorrhage.

 

For further information, please email us at enquiry@selentus.com, or contact (+44) 7565 825 662. In Asia-Pacific please contact (+852) 6200 8250.

Selentus' patent protecting TenaTac® has been granted in China (patent number CN 108136080 B). The patent is also pending in other territories worldwide.​

​

For further information, please email us at enquiry@selentus.com, or contact (+44) 7565 825 662. In Asia-Pacific please contact (+852) 6200 8250.

Selentus' patent protecting TenaTac® has been granted in Brazil (patent number BR 112018007612-0 B1). The patent is also pending in other territories worldwide.​

​

For further information, please email us at enquiry@selentus.com, or contact (+44) 7565 825 662. In Asia-Pacific please contact (+852) 6200 8250.

Selentus is pleased to announce that it has won the Innovation Award at the Medilink Midlands Business Awards 2021 competition. This award was given for the development of innovative technology that has produced a major improvement in business performance and impacted the market. For further details, please visit: https://www.medilinkem.com/double-winners-at-the-medilink-midlands-business-awards/

​

For further information, please email us at enquiry@selentus.com, or contact (+44) 7565 825 662. In Asia-Pacific please contact (+852) 6200 8250.

Selentus' patent protecting TenaTac® has been granted in Japan (patent number JP 6854825). The patent is also pending in many other territories worldwide.​

​

For further information, please email us at enquiry@selentus.com, or contact (+44) 7565 825 662. In Asia-Pacific please contact (+852) 6200 8250.

Selentus' patent protecting TenaTac® has been granted in the U.K. (patent number GB 2543307). The patent is also pending in many other territories worldwide.​

​

For further information, please email us at enquiry@selentus.com, or contact (+44) 7565 825 662. In Asia-Pacific please contact (+852) 6200 8250.

Selentus is pleased to announce the launch of its flagship TenaTac® haemostatic agent for the veterinary market. TenaTac® will be sold to veterinary surgeons in the U.K by Selentus Science. 

 

For further information, please email us at enquiry@selentus.com, or contact (+44) 7565 825662.

Selentus' patent protecting TenaTac® has been granted in the U.S.A. (patent number US 10,653,821). The patent is also pending in many other territories worldwide.​

​

For further information, please email us at enquiry@selentus.com, or contact (+44) 7565 825 662. In Asia-Pacific please contact (+852) 6200 8250.

Selentus Science Ltd is pleased to report that its partner CuraMedical BV (the Netherlands) has obtained regulatory approval for TenaTac® in the European Union. TenaTac® is an absorbable haemostat with improved tissue adhesion and is indicated for intra-operative surgical bleeding. The product will be marketed in Europe by CuraMedrix BV (the Netherlands). Dr Ben Nichols, Selentus’ Chairman, commented that TenaTac has great potential in the European market and they anticipate further partnerships in North America and Asia-Pacific.

 

For further information, please email us at enquiry@selentus.com, or contact (+44) 7565 825 662. In Asia-Pacific please contact (+852) 6200 8250.